Insider Sell: BioMarin Pharmaceutical
1:32PM ET 5/04/2022 MT NewswiresGeorge Eric Davis, Executive Vice President, Chief Legal Officer, on April 29, 2022, sold 15,347 shares in BioMarin Pharmaceutical (BMRN) for $1,233,592....
George Eric Davis, Executive Vice President, Chief Legal Officer, on April 29, 2022, sold 15,347 shares in BioMarin Pharmaceutical (BMRN) for $1,233,592....
Richard A Meier, Director, on May 02, 2022, sold 3,878 shares in BioMarin Pharmaceutical (BMRN) for $318,345. Following the Form 4 filing with the SEC,...
Jean Jacques Bienaime, Director, Chief Executive Officer, on April 28, 2022, sold 25,000 shares in BioMarin Pharmaceutical (BMRN) for $2,085,550. Following...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Address | 770 Lindaro Street San Rafael, California 94901 |
Phone | +1.415.506.6700 |
Number of Employees | 2,849 |
Recent SEC Filing | 05/11/2022![]() |
Chairman & Chief Executive Officer | Jean-Jacques Bienaimé |
Chief Financial Officer & Executive VP-Finance | Brian R. Mueller |
Chief Information Officer | Eduardo E. von Pervieux |
President-Worldwide Research & Development | Henry J. Fuchs |
Price Open | $78.30 |
Previous Close | $79.12 |
52 Week Range | $71.59 - 94.20 |
Market Capitalization | $14.6 B |
Shares Outstanding | 185.0 M |
Sector | Health Technology |
Industry | Biotechnology | Next Earnings Announcement | 07/27/2022 |
Call Open Interest (1d)* | ![]() |
Put Open Interest (1d)* | ![]() |
Call Volume (1d)* | ![]() |
Put Volume (1d)* | ![]() |
Put Call Open Interest Ratio (1d)* | ![]() |
Put Call Volume Ratio (1d)* | ![]() |
* Data delayed by up to 15 minutes |
Price / Earnings | 431.83 |
Earnings per Share | $0.21 |
Beta vs. S&P 500 | N/A |
Revenue | $1.5 B |
Net Profit Margin | 2.10% |
Return on Equity | 0.92% |
Buy | |
Overweight | |
Hold | |
Underweight | |
Sell | |
Consensus Recommendation![]() |